Aprea Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
CEO Oren Gilad and CFO John P. Hamill certified the Q3 2026 10-Q filing (period ended September 30, 2026, filed November 4, 2026) per Sarbanes-Oxley Sections 302 and 906. Both officers certify the report contains no untrue material statements, that financial statements fairly present the company's condition and operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Boilerplate SOX compliance certification. No operational changes, transactions, or financial specifics disclosed. Routine quarterly filing requirement.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.